Table 1 Subject’s baseline data at the start of the study
Parameters | Patients treated with Amla Extract (Mean ± S.D) | Patients treated with Placebo (Mean ± S.D) | p-value |
|---|---|---|---|
Age (years) | 40.7 ± 10.13 | 42.2 ± 9.20 | 0.44 |
Height (cm) | 162.7 ± 9.20 | 163.1 ± 9.54 | 0.82 |
Weight (kg) | 70.4 ± 10.57 | 69.8 ± 9.04 | 0.75 |
Number of participants | 49 | 49 | Â |
Number of male subjects | 22 | 23 | 0.84 |
Number of female subjects | 27 | 26 | Â |
Body Mass Index (BMI; Kg/m2) | 26.9 ± 3.77 | 26.1 ± 3.39 | 0.27 |
Systolic Blood Pressure (mmHg) | 118.1 ± 5.77 | 119.7 ± 5.19 | 0.15 |
Diastolic Blood Pressure (mmHg) | 77.9 ± 6.87 | 77.4 ± 7.06 | 0.72 |
Heart Rate (Beats per minute) | 77.5 ± 6.11 | 77.1 ± 6.52 | 0.75 |
Axillary Temperature (degrees Celcius) | 36.96 ± 0.243 | 36.94 ± 0.308 | 0.72 |
Total cholesterol (mg/dL) | 231.7 ± 27.03 | 225.7 ± 29.03 | 0.27 |
Triglycerides (mg/dL) | 261.1 ± 74.13 | 247.6 ± 57.70 | 0.84 |
High Density Lipoproteins (mg/dL) | 43.7 ± 7.45 | 43.4 ± 7.34 | 0.09 |
Low Density Lipoproteins (mg/dL) | 140.0 ± 19.66 | 132.2 ± 20.82 | 0.06 |
Very Low Density Lipoproteins (mg/dL) | 51.7 ± 15.9 | 49.6 ± 11.68 | 0.70 |
Atherogenic index of Plasma | 0.43 ± 0.14 | 0.41 ± 0.12 | 0.82 |
Fasting Plasma Glucose (mg/dL) | 90.6 ± 26.83 | 91.9 ± 22.12 | 0.44 |
Ratio of Apo B to Apo A1 | 1.0 ± 0.34 | 0.87 ± 0.22 | 0.35 |
CoQ10 (ng/ml) | 471.5 ± 183.5 | 487.0 ± 167.5 | 0.27 |
HMGCoA (ng/ml) | 62.4 ± 11.06 | 53.4 ± 7.07 | 0.48 |
Glycolated Hb | 6.25 + 1.05 | 6.22 + 1.11 | 0.47 |
Homocystiene (μmol/L) | 23.58 ± 14.57 | 21.4 ± 11.10 | 0.36 |
TSH (μIU/ml) | 2.43 ± 1.50 | 2.53 ± 2.58 | 0.33 |
CRP | 3.71 + 5.82 | 4.58 + 5.96 | 0.10 |
Blood Urea (mg/dl) | 9.7 ± 3.42 | 10.2 ± 5.39 | 0.93 |
Hb | 14.03 ± 2.34 | 13.89 ± 2.04 | 0.48 |
Serum Creatinine-(mg/dl) | 0.8 ± 0.15 | 0.9 ± 0.60 | 0.64 |
Serum Bilirubin-(mg/dl) | 0.6 ± 0.32 | 0.6 ± 0.28 | 0.28 |
SGOT (U/L) | 27.2 ± 10.23 | 27.4 ± 9.35 | 0.98 |
SGPT (U/L) | 38.6 ± 20.86 | 37.2 ± 18.56 | 0.88 |